The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Improving Outcomes in Pancreatic Cancer With Perioperative mFOLFIRINOX

Davendra Sohal, MD, MPH
Published Online:2:16 PM, Tue September 26, 2017

Davendra Sohal, MD, MPH, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the need for an ongoing study exploring mFOLFIRINOX versus gemcitabine and nab-paclitaxel (Abraxane) in patients with resectable pancreatic adenocarcinoma.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.